Pack Article Directory Federated States of Micronesia: DDAVP

DDAVP is a brand name of desmopressin, approved by the FDA in the following formulation(s):

DDAVP (desmopressin acetate - injectable; injection)

Manufacturer: SANOFI AVENTIS US

Approval date: March 30, 1984

Strength(s): 0.004MG/ML ^[RLD]^[AP]

DDAVP (desmopressin acetate - solution; nasal)

Manufacturer: SANOFI AVENTIS US

Approved Prior to Jan 1, 1982

Strength(s): 0.01% ^[RLD]

DDAVP (desmopressin acetate - tablet; oral)

Manufacturer: SANOFI AVENTIS US

Approval date: September 6, 1995

Strength(s): 0.1MG ^[AB], 0.2MG ^[RLD]^[AB]

Has a generic version of DDAVP been approved?

A generic version of DDAVP has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to DDAVP and have been approved by the FDA:

desmopressin acetate injectable; injection

Manufacturer: HOSPIRA

Approval date: August 28, 2000

Strength(s): 0.004MG/ML ^[AP]

Manufacturer: TEVA PARENTERAL

Approval date: October 15, 1997

Strength(s): 0.004MG/ML ^[AP]

desmopressin acetate tablet; oral

Manufacturer: APOTEX INC

Approval date: March 7, 2006

Strength(s): 0.1MG ^[AB], 0.2MG ^[AB]

Manufacturer: TEVA PHARMS

Approval date: January 25, 2006

Strength(s): 0.1MG ^[AB], 0.2MG ^[AB]

Manufacturer: WATSON LABS

Approval date: July 1, 2005

Strength(s): 0.1MG ^[AB], 0.2MG ^[AB]

Note: No generic formulation of the following product is available.

desmopressin acetate - solution; nasal

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of DDAVP. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Process for manufacture of 1-deamino-8-D-arginine vasopressin
Patent 5,500,413
Issued: March 19, 1996
Inventor(s): Larsson; Krister & Mellbrand; Thomas & Mornstam; Birgitta & Roschester; Jan & Skoldback; Jan-Ake
Assignee(s): Ferring AB
A process for the manufacture of 1-deamino-8-D-arginine vasopressin (DDAVP) comprising, condensing a preparation of Mpa(R.sup.1)-Tyr-Phe-Gln-Asn-Cys(R.sup.2)-Pro-OH (SEQ ID NO: 1), where R.sup.1 and R.sup.2 are sulfhydryl-protecting groups, with the dipeptide (R.sup.3)-D-Arg(HCl)-Gly-NH.sub.2, where R.sup.3 is an acid-sensitive amino-protecting group, to form Mpa(R.sup.1)-Tyr-Phe-Gln-Asn-Cys(R.sup.2)-Pro-D-Arg(HCl)-Gly-NH.sub.2 (SEQ ID NO: 1), which is oxidized with iodine in a protic solvent. The reaction mixture containing the oxidized product can be purified by ion exchange chromatography on a cation exchange resin equilibrated with acid. Also disclosed is high-purity DDAVP obtained by this process and its use for treating diurea.
Patent expiration dates:
- June 29, 2013

High purity desmopressin produced in large single batches
Patent 5,674,850
Issued: October 7, 1997
Inventor(s): Larsson; Krister & Mellbrand; Thomas & Mornstam; Birgitta & Roschester; Jan & Skoldback; Jan-Ake
Assignee(s): Ferring AB
A process for the manufacture of high purity desmopressin produced in single batches of substantial size and a method of treating diabetes insipidus with the high purity desmopressin produced therefrom.
Patent expiration dates:
- December 23, 2013

High-purity desmopressin produced in large single batches
Patent 5,763,407
Issued: June 9, 1998
Inventor(s): Larsson; Krister & Mellbrand; Thomas & Mornstam; Birgitta & Roschester; Jan & Skoldback; Jan-Ake
Assignee(s): Ferring BV
A process for the manufacture of high purity desmopressin produced in single batches of substantial size and a method of treating diabetes insipidus with the high purity desmopressin produced therefrom.
Patent expiration dates:
- June 29, 2013

Pharmaceutical composition as solid dosage form and method for manufacturing thereof
Patent 7,022,340
Issued: April 4, 2006
Inventor(s): Lomryd; Hakan & Nicklasson; Helena & Olsson; Lars-Erik
Assignee(s): Ferring B.V.
The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof; wherein the pharmaceutical composition is composed of a compressed granulate and contains lubricant in an amount of from 0.05 to less than 0.50 percent by weight of said pharmaceutical composition.
Patent expiration dates:
- April 30, 2023
  ✓
  Drug product

Pack Article Directory Federated States of Micronesia

Tuesday, September 6, 2016

DDAVP